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Abstract 
We present N.K, a 31-year old male from Kenya, East Africa, who is a kidney graft recipient from 2013. He 
suffered endstage kidney disease from poorly controlled hypertension. Subsequently was transplanted from a 
living related haploidentical donor. He presented barely two years later with asthenia, general body malaise and 
back pain. He was diagnosed with an abscess in the transplanted renal bed in the right iliac fossa, which yielded 
Mycobacteria tuberculosis on polymerase chain reaction, which was rifampicin sensitive. We started him on an 
anti-TB  regimen which include isoniazid, pyrazinamide, ethambutol and moxifloxacin. Tuberculosis poses 
diagnostic and treatment challenges in transplant recipients. Balancing  between drug-drug interactions, and 
raising immunity without adversely affecting the kidney graft  is paramount. 
Keywords: Kidney transplantation; Kidney graft recipient; Mycobacteria tuberculosis infection in transplant 
recipients. 
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1. Introduction  
N.K.  was  27 year-old male by the time he was referred to a nephrologist in 2011 by a physcian. He was 
referred with diagnosis of chronic kidney disease probably from chronic glomerulonephritis with target organ 
damage.  He was on nifedipine 40 mg twice daily, furosemide 40 mg  once daily and carvedilol 12.5mg twice 
daily. He had developed  hemiparesis a month prior to  presentation to the nephrologist. Conservative 
management for the chronic kidney disease was continued with intensification of blood pressure control. In 
April 2013, arterio-venous fistula was created in the left antecubital  in anticipation for dialysis which he started  
later. In October 2013, he got kidney graft transplant, from living-related donor, female, 31 year- old, blood 
group O, rhesus positive, Human Leucocyte Antigen (HLA) mismatch 3/6.  He was started on tacrolimus 2.5 mg 
twice, prednisone and mycophenolate mofetil 720mg twice daily. Peritransplantation period was unremarkable.  
In 2015 August, he presented with general ill-health, backpain, weight loss. In October 2015, he presented with 
fever, progressive weight loss for last 6 months from 70 to 50 kg,  severe lower back pain with associated 
difficult in walking. Examination revealed tenderness at the lower back around fourth and fifth lumbar spines. 
Urinalysis showed leucocyturia, chest radiograph was normal.  Radiograph of the lumbosacral region was 
unremarkable. Magnetic resonance imaging of the pelvis revealed  lesion behind the graft kidney in the right 
iliac fossa.. 
 
Figure 1: Chest radiograph  
 
Figure 2: Pelvic radiograph 
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    Figure 3: MRI Abdominopelvis 
Ultrasound scan of the lumbar mass with aspiration  yielded pus. Microbiologic studies: –Polymerase chain 
reaction for Mycobacteria: Mycobacteria detected which was rifampicin sensitive. Routine microscopy: scanty 
leucocytes and erythrocytes. No bacteria, no fungal elements seen. Bacterial cultures:  Aerobic and anaerobic 
cultures: no growth obtained.  
The kidney functions from February 2015 to October 2015 were: Sodium 121 – 137 mmol/L, potassium 3.5 - 
4.3 mmol/L, urea 3.7- 7.94 mmol/L, creatinine 81-125 μmol/L. The haemogram parameters during this period 
were: Leucocytes counts: 6.62 -16.2 X 109/L, relative count of granulocytes from 63-76.7% and lymphocytes 
16.8-29%. Erythrocytes counts were 5.28-6.34 X 1012/L, mean corpuscular volume at 66.7 – 76.5fL, and 
haemoglobin levels  13.4 – 15.8 g/dL. The tacrolimus plasma trough levels ranged between 4 – 5.4 ng/mL.  
N.K was initiated on anti-mycobacteria tuberculosis treatment with isoniazid 300mg, ethambutol 600mg, 
pyrazinamide1500 mg and moxifloxacin 400mg once daily in the intensive phase for two months  with a plan to 
continue with ethambutol 600mg , isoniazid 300 mg and moxifloxacin 400mg for 10 months  in the continuation 
phase, to cover a total treatment period of 12 months. 
Three months after initiation of treatment, N.K has shown pleasant progress with renal functions, liver 
functions, blood counts, plasma tacrolimus trough levels, and general well being showing marked improvement. 
His creatinine has ranged from 64 to 95 μmol/L, urea 5.5  to 9.0 mmol/L. The tacrolimus plasma trough levels 
have been between 4.4 and 9.6 ng/mL. He has generally showed marked improvement and the pain subsided. 
His tacrolimus dose had been 1.5mg twice daily. 
2. Discussion and Literature Review 
Tuberculosis (TB) has plagued humankind for thousands of years worldwide. It is likely to have existed in 
prehominids.  John Bunyan (Nov 28, 1628–Aug 31, 1688), described tuberculosis as “The Captain among these 
men of death” at a time when tuberculosis case rates in London had reached 1000 per 100 000 population per 
year [1]. Risk factors which have been documented for development of tuberculosis include human 
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immunodeficiency virus infection which increases the risk by 20 – 37 times depending on country HIV 
prevalence [2, 3]. Diabetes mellitus type 1 increases the risk of TB infection by about 3 times [4, 5],  end-stage 
renal failure increases the risk by more than 10 times [6], solid organs and haematological malignancies 
associated with increased risk [7, 8] while corticosteroid therapy increases the risk by about two times [9]. N.K 
had chronic kidney disease, later he was on corticosteroids since 2013 and this could have predisposed him to 
developing TB.   The commonest form of tuberculosis is pulmonary, although for N.K, no pulmonary focus was 
evident.  Extrapulmonary TB posses a more difficult diagnostic challenge when compared  with pulmonary TB. 
However, pulmonary tuberculosis is more common (almost twice) in non-transplant recipients than in transplant 
recipients. Disseminated tuberculosis is more frequent in transplant recipients (five times more) when compared 
with non-transplant patients [10].  Comparison of tuberculosis in transplant and non-transplant found three times 
more factors predisposing transplant recipients to TB when compared with non-transplant non-HIV cases. Time 
from clinical suspicion of tuberculosis to definitive diagnosis was longer in transplant recipients than in non-
transplants. Invasive procedures were  three times more required in  transplant recipients than in non-transplants 
[10]. This was the case for N.K, where the chest radiographs were unremarkable and had no sputum production. 
The diagnosis was got from pus drained from the grafted kidney bed abscess.  
In solid organ recipients, while TB may be donor-transmitted or community-acquired, it usually develops at a 
latent infection site in the recipient. Mycobacterium tuberculosis can be transmitted by transplantation which  
has been estimated previously to account for 4% of the reported post-transplant TB cases [11]. For N.K. the 
donor had N.K.  were both screened for pulmonary tuberculosis before transplantation, which were negative.  
Immunosuppression with one or both of tacrolimus and mycophenolate mofetil has been associated with the 
development of TB at a younger age and at a higher frequency during the first 6 months after transplantation 
when compared with conventional therapy [12]. N.K had been on both tacrolimus and mycophenolate mofetil.  
The major immunosuppressive agents that are currently being used are corticosteroids (oral prednisone), 
azathiaprine, or  mycophenolate mofetil  and cyclosporine  or tacrolimus. The optimal dose of maintenance 
immunosuppressive therapy in renal transplantation has not been established. The incidence of opportunistic 
infections increases when such potent agents are used. In a large European trial, treatment with cyclosporine and 
tacrolimus  was associated with the development of infection in about 40% of patients, sepsis in 20% and 
cytomegalovirus infection in 15–25% [13].  
2.1 Prevalence of tuberculosis in transplant recipients 
The prevalence of tuberculosis in transplant recipients is higher than in general population. Solid organs 
transplantation (SOT) is a well established predisposition to development of TB. Development of TB infection 
in SOT recipients occurs in the first year post-transplantation [14] in most cases, but a bi-modal distribution has 
also been observed, with the incidence of TB at a peak 2 years after SOT[15, 16]. In Europe, the incidence of 
TB in solid organs transplant  (SOT) recipients  has previously been reported to be as high as 3.5% [17], lower 
rates have been reported recently (0.45–0.9%), [14, 18, 19]. The highest incidence (6.4–10%) has been observed 
in lung transplant recipients [20-22]. The percentage of SOT recipients who develop extrapulmonary or 
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disseminated TB is higher than in the general population [11, 16, 18, 23].  The incidence of TB among organ 
recipients is as much as 74- times that of the general population [11]. In 14 French transplant centres, between 
1986-2006, among 16146  kidney transplant recipients, 0.45% developed TB. Extrapulmonary and disseminated 
TB accounted for 67.4% of cases. The most common symptoms were fever (71.7%) weight loss (41.3%) and 
asthenia (39.1%) [24]. All these were present in N.K.  In India, Post-transplant tuberculosis has been reported to 
occur in 12 to 20% of patients, and results in 20 to 25% of those patients [25]. In Tunisia, from 1986 to 2009,  
among 491 renal transplant recipients, the prevalence of TB was 3.2 % with an overall incidence of TB being 
72/100 kidney transplant recipient/year, whose presentations were sterile leucocyuria, graft dysfunction and 
biological inflammatory syndrome [26]. Pulmonary TB was noted in more than 60% of the cases, with 
extrapulmonary in almost 20% in this population. 
2.2 Clinical presentations 
In SOT recipients, symptoms of infection are often attenuated, leading to delayed diagnosis. The most common 
symptoms are fever, weight loss, and asthenia [24]. Diagnosis of extrapulmonary TB is difficulty of  to make, 
which often leads to empirical treatment without pathological or bacteriological confirmation [27]. In 
developing countries, the problems of diagnosis are compounded by a lack of diagnostic resources. TB may not 
be considered at all in the differential diagnosis, resulting in delay or deprivation of treatment  [28]. 
Extrapulmonary forms of tuberculosis occur in all age groups, adding to diagnostic and treatment difficulties. 
Clearly, it took time for us to make the diagnosis in N.K. 
2.3 Latent tuberculosis infection 
Latent TB infection (LTBI) is infection with Mycobacteria Tuberculosis Complex (MTC) at an early stage with  
viable organism in a dormant state. There lacks a reference standard to diagnose LTBI.  Diagnosis is usually  
made by documenting a positive tuberculin skin test (TST) in a person who has no signs, symptoms or chest 
radiograph evidence of active TB disease  [29].  False-negative TST  results occur in  anergic patients, such as 
those receiving immunosuppressive therapies and/or affected by chronic kidney and liver disease, and this 
excluded using TST in N.K. False-positive results occur in areas in which Bacillus Calmette–Guérin (BCG) 
vaccination is prevalent or when there is accidental exposure to environmental non-tuberculous mycobacteria 
(NTM), this too excluded TST from being used for diagnosis in N.K.  
Novel blood tests have become available which detect gamma interferon production in response to antigens 
encoded by the section of MTB DNA called region of deletion 1 (RD1), which  is present in virulent MTB 
strains but is deleted in all attenuated Mycobacterium bovis BCG vaccine strain genome [30]. These tests, now 
known as interferon gamma release assays (IGRAs). They are  more specific (presenting no cross-reactivity 
with BCG and NTM) and less affected by immunosuppressive therapies, despite undergoing the same inhibition 
of immune mechanisms that is responsible for the impaired performance of TST. Two commercially produced 
IGRAs are available. Both tests employ a mitogen-induced positive control able to differentiate between an 
anergic and a true negative response. With both tests, the result may be reported as qualitative 
(positive/negative) or quantitative according to defined cut-off values. Quantitative results seem more accurate 
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in detecting the progression of TB infection [31-34]. Interferon gamma release assays presented higher 
positivity than TST and provided a more accurate reflection of the risk of LTBI among kidney transplant 
candidates [35] and also showed a role in predicting subsequent TB development in kidney transplant recipients 
in whom TST did not detect LTBI [36]. Use of interferon gamma release assay and tuberculin skin test for 
diagnosis of latent tuberculosis infection in kidney transplant recipients showed reasonable concordance but no 
superiority of either test [37]. Tuberculosis is a very serious complication in SOT recipients and both TST and 
IGRAs may have false-positive and negative results, however, their concurrent use would be the ideal approach 
for increasing diagnostic sensitivity [34].  IGRA  was negative for our patient N.K. 
2.4 Active TB 
A diagnosis of TB can only be confirmed by culturing MTC or by identifying specific nucleic acid sequences in 
a clinical specimen collected from the suspected site of disease, with culture being the most sensitive detection 
method. Growth is necessary for definitive species identification and full drug susceptibility testing (DST) [38].  
2.5 Treatment  of Active TB in  Pre-transplant 
For the purposes of treatment, extrapulmonary tuberculosis can be classified into severe and non-severe forms. 
Severe forms include meningeal tuberculosis, spinal tuberculosis, neuro-tuberculosis, abdominal tuberculosis, 
bilateral pleural effusion, pericardial effusion, and bone and joint tuberculosis involving more than one site. 
Extrapulmonary tuberculosis of other sites is classified as non-severe [39]. In SOT recipients no efforts should 
be spared in search for TB. When active TB cannot be ruled out, the worst case scenario should be assumed and 
initiation of TB treatment with the standard three drugs. If cultures for MTC are negative after the  8th week of 
incubation, treatment can be completed with isoniazid alone [40]. Patients with active TB should not undergo 
transplantation.  
2.6 Treatment of Active TB in Post-transplant 
The adverse effects of TB  therapy present a major difficulty, due to the interactions with immunosuppressive 
drugs and direct drug toxicity [41]. A standard 6-month regimen including rifampicin for TB treatment, in 
accordance with the currently available guidelines for the general population [42, 43].  It is reasonable to use a 
prolonged course of treatment in the immunosuppressed SOT population [40].  For N.K. we choose to treat him 
for 12 months. However, there are no randomized controlled trials assessing the optimal schedule and duration 
of TB therapy in SOT recipients so far.  Treatment of TB in SOT differs from that of general population in 
several aspects. The interactions between rifamycins and immunosuppressants, and the potential for 
hepatotoxicity associated with first-line TB therapy [40]. Many first-line anti-TB drugs (isoniazid, streptomycin 
and ethambutol) warrant dose adjustment in renal transplant patients. The use of rifamycins remains 
controversial. The interaction between rifampicin and calcineurin inhibitors, inhibitors of the mammalian target 
of rapamycin (mTOR) and corticosteroids is known to increase the risk of acute rejection [44-48]. The use of 
rifampin has been identified as a risk factor for immune reconstitution syndrome (IRS) related to changes in 
immunosuppressive treatment [49] though studies in populations other than SOT recipients have shown an 
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increased risk of TB recurrence and high TB resistance rates when rifamycin-sparing regimens are used [43, 
50]. There are difficulties adjusting immunosuppressive drug serum levels and a high graft failure rate with 
rifampicin usage [51-53]. For these reasons, we chose to omit rifampicin in our treatment regime for N.K. 
Recent series have observed no difference in post-tuberculosis rejection rate or mortality between patients who 
did or did not receive rifampicin-based regimens [14, 54] and these drugs may be safe with rigorous control of  
immunosuppressive drug levels [17, 55, 56]. In HIV patients, rifabutin appears to be as efficacious as 
rifampicin, thus, it might be an alternative in SOT recipient and has shown fewer interactions with 
immunosuppressive drugs [40]. The benefits of rifamycins must be balanced against the risk of rejection. 
Physicians may weigh the risks and benefits before including rifamycins in the anti-TB regimen in SOT 
recipents. If rifampin use is mandatory, the dose of calcineurin inhibitors and mTOR should be increased 
between three and  five-fold (increasing the frequency of administration from twice to thrice daily) and the 
corticosteroid dose should be doubled [11, 15, 44, 57-60]. Levels of immunosuppressants should be closely 
monitored for both kinds of rifamycins.  
2.7 Regimens including rifamycins 
In rifampicin- or rifabutin-containing  regimens, a standard treatment based on a three-drug  regimen may be 
considered with the exception of  high isoniazid-resistant regions. Completing treatment with isoniazid and 
rifampicin or rifabutin in the maintenance phase for at least 9 months is rational [40], for treatments duration 
less than 9 months have been associated with an increased mortality rate [15], while  a 9–12 month period of 
anti-tuberculosis treatment  have been shown to reduces the risk of recurrence or treatment failure rates [55, 61]. 
When regimen of isoniazid, rifampin and pyrazinamide are used, hepatic function monitoring is mandatory as 
these drugs  may cause significant hepatotoxicity [15, 43, 61-63]. Pyrazinamide could be replaced with a 
fluoroquinolone in shorter course regimen. Extended treatment duration of 12-18 months have been suggested in 
patients with cavitory pulmonary TB whose culture remains positive after 2 months of treatment [40, 56, 64-66].  
2.8 Regimens that do not include rifamycins 
Voidance of rifamycins is a common practice in TB treatment in SOT recipients owing to the  interactions of 
transplant drugs with rifamycins. If  rifamycin-free therapy is used, prolonged treatment duration of 12-18 
months  has been considered for SOT patients due to the experience gained in the general population [11].  In 
rifamycin-free treatment regimens, a combination therapy with isoniazid and ethambutol for 18 months with the 
addition of pyrazinamide for the first 2 months  has been proposed [57]. Maintenance agents may include 
isoniazid and pyrazinamide or ethambutol, and the possible addition of levofloxacin/moxifloxacin should be 
considered; a three-drug regimen may reduce the treatment length [40]. Favourable experiences with the use of 
isoniazid, pyrazinamide and ethambutol for the first 2 months, followed by a 12- to 18-month course of 
complete therapy have been reported [55, 67]. Fluoroquinolones (FQs) are an alternative for transplant patients 
because of the disadvantages associated with rifamycins and aminoglycosides [68]. In the transplant setting, 
good outcomes with FQs in the initial four-drug regimen for kidney and lung transplant recipients have been 
described [20, 69, 70]. The preliminary results of two quinolones-containing regimens, the RIFAQUIN trial 
(moxifloxacin and rifapentine twice weekly in place of rifampicin and isoniazid) [71] and the OFLOTUB trial 
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(gatifloxacin instead of ethambutol), showed the inferiority of 4-month TB regimens for outcome [72]. The 
possibility that the widespread use of FQs for other infections could lead to a high prevalence of FQ-resistant 
TB is a matter for concern [73]. Prolonged use of fluoroquinolones may be associated with arthralgias  [16]; it 
may enhance the risk of tendon-related side-effects of corticosteroids, and a combination may decrease 
mycophenolate levels. Levofloxacin may increase cyclosporine levels [74]and its combination with 
pyrazinamide is associated with poor digestive tolerance [75]. Linezolid has proven to be effective for patients 
with TB [76], though prolonged use of this drug has been associated with thrombopenia, anaemia and 
polyneuropathy, especially in patients with diabetes or kidney disease. 
2.9 Drug-resistant Tuberculosis 
Multidrug-resistant (MDR) TB is defined as resistance to both isoniazid and rifampin and extremely drug-
resistant (XDR) TB is defined as resistance to isoniazid, rifampin, fluoroquinolones and at least one injectable 
drug like mikacin, kanamycin and capreomycin [77]. Public health action is needed to improve treatment 
outcomes in regions where drug-resistant TB is prevalent [78]. Few case reports of MDR-TB in SOT recipients 
have been published [79-81]. In non-SOT individuals with MDR-TB infection, treatment with second-line anti-
TB therapy for 18–24 months achieved a 75% long-term success rate [82]. If isoniazid and rifamycins cannot be 
used, induction treatment should include four to six drugs, including injectable antimicrobials. Evidence is 
lacking on the recommended treatment duration for these regimens, but  up to 2 years following MTC culture 
conversion is reasonable [83]. 
2.10 Prevention of TB in Kidney transplant recipient 
Cochrane review of  on antibiotic prophylaxis for preventing post solid organ transplant tuberculosis found 
evidence in favour for TB prophylaxis administered to all kidney transplant recipients in TB-endemic regions 
during the first year post-transplant [84] . 
3. Recommendations  
Tuberculosis infections and organ transplantation require more evidence and long term follow up with close 
monitoring to maintain sufficient immunity without compromising the grafted organ function. Studies in among 
the transplant populations will shed more light into the complexity of the care in Tuberculosis treatment and 
immunosuppressive therapies.   
4. Conclusion  
Tuberculosis infection poses challenges in transplant population. The recipients are predisposed to the infection 
due to the primary disease like chronic kidney disease, treatment of the primary disease which include 
transplantation which makes the patients to be on long term immunosupression. Diagnosis of TB can be 
challenging in this population and may take protracted course. Treatment of the TB requires balancing act 
between the transplanted organ function and achieving cure without losing the patient to the disease. This is 
mainly due to drugs interactions. More studies are required in this field of transplantation and TB. 
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